All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 2nd How to Diagnose & Treat CML / MPN, the MPN Hub spoke to Tiziano Barbui, Papa Giovanni XXIII Hospital, Bergamo, IT. We asked, What needs to be considered in patients with MPN with COVID-19?
What needs to be considered in patients with MPN with COVID-19?
To introduce the topic, Barbui discusses a Swedish population-based study that reported that patients with MPN and myelofibrosis were particularly vulnerable to infections. He gives a thorough discussion on the results of an international study evaluating patients with different phenotypes of MPN and COVID-19 conducted by the European LeukemiaNet (ELN). Notably, Barbui believes that patients with MPN with COVID-19 taking ruxolitinib should not discontinue treatment during the acute COVID-19 phase due to its anti-inflammatory properties. Finally, Barbui touches upon the response rate of patients with MPN to COVID-19 vaccines.
Subscribe to get the best content related to MPN delivered to your inbox